Figure 2. Exosomal SOX2-OT increases proliferation and attenuates apoptosis of ovarian cancer cells. (A) The characteristics of exosomes were measured by the TEM in the TOV-21G and SKOV-3 cells. (B) The expression of CD9 and CD63 was tested by the Western blot analysis in the exosome of TOV-21G and SKOV-3 cells. (C) The expression of SOX2-OT was analyzed by qPCR in the TOV-21G and SKOV-3 cells treated with RNase A (1 μg/mL) or co-treated with RNase A (1 μg/mL) and Triton X100 (0.1%). (D–I) The TOV-21G and SKOV-3 cells were treated with the SOX2-OT shRNA or control shRNA, and the exosomes were extracted and further treated the cells. (D) The efficiency of the SOX2-OT knockdown was confirmed by qPCR assays in the cells. (E, F) The cell viability was assessed by the MTT assays in the cells. (G) The cell proliferation was determined by colony formation assays in the cells. (H) The cell apoptosis was examined by flow cytometry analysis in the cells. (I) The expression of Bcl-2, Bax, cleaved-caspase3, and caspase3 was measured by Western blot analysis in the cell. Data are presented as mean ± SD. Statistic significant differences were indicated: * P < 0.05, ** P < 0.01, *** P < 0.001.